EN DE
Watch Pacific Biosciences of California for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Pacific Biosciences of California (PACB) stock: price, quality, comparison

Price, quality, revenue and earnings and the peer comparison for Pacific Biosciences of California, from audited financials.

Price: $2.26. Our models give no reliable value for this company right now, so we show no fair value.
  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PB Pacific Biosciences of California logo Thin data Jul 19, 2026

Pacific Biosciences of California

PACB · US
Mixed Growth (revenue 5y +15.2 %/yr in USD)
Negative equity (buybacks among others)
Insiders sold $2.1M (6M)
Quality 25/100
Loss-making · -82.5% net margin (TTM)
Negative free cash flow
Trails peers (1/7)
Narrow moat 0/100
Thin data
No fair value
Watch Pacific Biosciences of California for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.

Show moreShow less

The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.

It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.

In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument.

It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies.

The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data.

The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 64
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 7
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 85
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 59
Distance to the 52-week high, does not count
New shares 26
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $2.1M and none bought.

  • SaleJames R Gibson IIOfficer2× since Apr 1, 2026: 750,000 shares, avg. $2.90$2.2MOct 6, 2026
  • SaleMark Van OeneOfficer3× since Feb 17, 2026: 218,312 shares, avg. $1.54$335,123Aug 17, 2026
  • SaleMichele FarmerOfficer2× since Feb 17, 2026: 53,146 shares, avg. $1.59$84,510Mar 3, 2026
  • SaleChristian O HenryOfficer2× since Feb 17, 2026: 485,164 shares, avg. $1.59$772,728Mar 3, 2026

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+3.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.2%
Start year 2020 (pandemic). Over 10 years: +5.6% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−132.3% (2020) → −348.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch PACB, get fair value alerts →

Compare Pacific Biosciences of California with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −69.7% · Bottom 25%
Net margin (12 months) −82.5% · Bottom 25%
Operating margin (12 months) −114.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −1.9% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 4.63× · Pricier than median
EV/EBITDA 6.6× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $373.62 +15% vs PACB
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs PACB
DexCom, Inc DXCM $79.41 $87.35 +10% vs PACB
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥197.22 +7% vs PACB
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs PACB
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs PACB
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs PACB
Abbott Laboratories, ABT $109.93 $75.28 −32% vs PACB
Medtronic plc MDT $101.80 $65.61 −36% vs PACB
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs PACB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector

Frequently asked questions

What is the quality score of PACB?
Pacific Biosciences of California has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Pacific Biosciences of California (PACB)?
Pacific Biosciences of California reported trailing-twelve-month revenue of about $159M (latest available figure, as of Jul 19, 2026).
How solid is the balance sheet of Pacific Biosciences of California (PACB)?
Balance-sheet figures for Pacific Biosciences of California (as of Jul 19, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
Which stocks are comparable to Pacific Biosciences of California?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Pacific Biosciences of California (PACB)?
The closing price on Nov 6, 2026 was $2.26. We carry closing prices from our data provider, not a live tick.

Key figures of Pacific Biosciences of California

How large is the market capitalisation of Pacific Biosciences of California (PACB)?
The market capitalisation of Pacific Biosciences of California is $737M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pacific Biosciences of California (PACB)?
The price-to-sales ratio of Pacific Biosciences of California is 4.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pacific Biosciences of California (PACB)?
Earnings per share at Pacific Biosciences of California are $−0.4300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pacific Biosciences of California (PACB)?
The net margin of Pacific Biosciences of California is −82.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pacific Biosciences of California (PACB)?
The return on equity (ROE) of Pacific Biosciences of California is −929% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pacific Biosciences of California (PACB)?
On an EBIT basis the return on assets of Pacific Biosciences of California is −31.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pacific Biosciences of California (PACB)?
The operating margin of Pacific Biosciences of California is −114% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pacific Biosciences of California (PACB)?
Revenue at Pacific Biosciences of California is growing −1.9% versus a year earlier (3y avg +7.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pacific Biosciences of California (PACB) generate?
The free cash flow of Pacific Biosciences of California is −$114M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pacific Biosciences of California (PACB) carry?
The net debt of Pacific Biosciences of California is $696M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pacific Biosciences of California in the live analysis

One click puts Pacific Biosciences of California on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.